Metabolic•Dual Agonist
⚖️Tirzepatide
FDA-approved dual GIP/GLP-1 receptor agonist (Mounjaro/Zepbound). Up to 22.5% weight loss in SURMOUNT-1 trial. Currently the most effective approved anti-obesity medication.
Amino acids
39
Mol. weight
4813.5 Da
Half-life
~5 days
Availability
On inquiry
Amino acid sequence
GIP/GLP-1 dual agonistWhat Is Tirzepatide?
Tirzepatide (LY3298176) is a dual GIP/GLP-1 receptor agonist developed by Eli Lilly. FDA-approved as Mounjaro (T2D, 2022) and Zepbound (obesity, 2023). The SURMOUNT-1 trial demonstrated 22.5% body weight reduction at 72 weeks at 15mg — the highest for any approved pharmacological agent at the time.
Key Mechanisms
- GLP-1R agonism — appetite suppression and gastric emptying delay
- GIPR agonism — synergistically amplifies GLP-1R-mediated weight loss; adipose tissue effects
- Metabolic parameter improvement — HbA1c, triglycerides, blood pressure, HDL
Key References
- Jastreboff AM et al. "Tirzepatide once weekly for the treatment of obesity." N Engl J Med, 2022;387:205–216.
- Rosenstock J et al. "Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in T2DM." Lancet, 2021;398:143–155.
Related in Metabolic
⚖️Exercise Mimetic
MOTS-C
Mitochondria-encoded exercise mimetic peptide. Activates AMPK via AICAR, improves insulin sensitivity and drives fat oxidation — independently of insulin receptor signalling.
⚖️Phase II Champion
Retatrutide (LY3437943)
Triple GIP/GLP-1/glucagon receptor agonist. Phase II trial demonstrated 24.2% body weight reduction at 48 weeks — the highest ever recorded for a pharmacological agent.
⚖️GLP-1 Agonist
Semaglutide
GLP-1 receptor agonist. FDA-approved (Ozempic/Wegovy). Up to 15% weight loss in Phase III trials. Reduces cardiovascular events (SELECT trial). The benchmark for GLP-1 weight loss research.